Tag Archive for: Investment

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

/in

Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b […]

Read more

Weekly roundup: Approvals, patents and pricing: healthcare regulation heats up

/in

PDUFA action date for Hansa Biopharma’s imlifidase BLA set for December 19, 2026 Hansa Biopharma announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. 📺Optimum TV […]

Read more

Jefferies & London Life Sciences Week 2025

/in

Presented by Optimum Strategic Communications and Catalyst Advisors, this guide is your key to Europe’s biggest week in life sciences. Join global investors, executives, and innovators for a packed schedule of conferences, panels, and networking events. Plan ahead, connect smart, and make every moment count!

Read more

Alis Biosciences launches fund to free over USD$30 billion of capital trapped in listed development-stage life sciences and biotech companies

/in

Significant market inefficiencies have left over USD$30 billion of capital trapped in c.300 listed biotech companies worldwide that have experienced clinical or regulatory setbacks Fund provides efficient mechanism to help investors recoup and recycle trapped cash, while allowing residual science and IP to be developed Fund to be listed on public markets in due course […]

Read more

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council

/in

Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP) Scale Up call Funding to support commercialization of its groundbreaking bioresorbable vascular conduits EINDHOVEN, The Netherlands, 8 April 2025 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and […]

Read more